Pre conference Afternoon Short Course
Tuesday May 20 | 2:00- 5:00 AM | Westin Boston Waterfront | Boston, MA
Introduction to Drug Metabolism and Its Role in Drug Toxicity
This course is intended for chemists, biologists and scientists from related disciplines who have an interest in furthering their understanding of drug metabolism and its role in drug discovery and development. In addition to some basic concepts, several advanced experimental approaches to drug metabolism will be introduced such as newer hepatocyte models and microdosing. In addition, the importance drug metabolism to drug toxicity will be explored through examining evidence linking idiosyncratic toxicity with drug bioactivation to reactive metabolites. In silico tools to investigate reactive metabolite formation will be discussed. It is hoped that both novices as well as those with more extensive exposure to drug metabolism will find benefit in attending this course.
Topics to be covered:
- Basic concepts of drug metabolism
- Newer approaches to investigate in vitro and in vivo drug metabolism
- Biotransformation pathways
- Understanding the role of reactive metabolites in idiosyncratic drug toxicity
- Role of drug transporters in toxicity
- In silico tools to aid drug metabolism research
2:00 Speaker and Attendee Introductions
2:15 Course talk
3:10 Networking Coffee Break
3:30 Course talk (contd.)
4:30 Q&A with attendees
5:00 End of course
John Erve, Ph.D., D.A.B.T., Jerve Scientific Consulting, Inc.
Dr. John Erve is from Chicago and received degrees in Chemistry (BS, MS) from the University of Chicago and earned a Ph.D in Toxicology at Oregon State University under the supervision of Dr. Donald Reed. Following postdoctoral work at Vanderbilt (1995-1999) he joined BD-Biosciences (Woburn, MA) as a Study Director. In 2002, he joined AstraZeneca (Sweden) where he was involved in characterizing reactive metabolites and their protein adducts in an effort to better understand the role of reactive intermediates in drug toxicity. In 2004 he joined Wyeth (Collegeville, PA) as a Principal Scientist responsible for metabolite identification. Following the merger with Pfizer in 2010, John joined Novartis Institutes of Biomedical Research (Cambridge, MA) as a Lab Head in Analytical Sciences. John returned to the field of drug metabolism by joining Elan Pharmaceuticals (San Francisco, CA) in 2012 and after Elan was sold created Jerve Scientific Consulting focusing on helping small biotech companies in the Bay area with their drug discovery efforts. His research interests include mechanistic toxicology and using mass spectrometry to characterize metabolites and metabolic pathways.
Back To Short Courses